Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

This study is comparing two maintenance treatment approaches for multiple myeloma (a blood cancer affecting plasma cells in the bone marrow) — using ixazomib + dexamethasone (Id) versus lenalidomide + dexamethasone (Rd) — after patients have achieved a good response from initial treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with multiple myeloma - You have already completed first-line treatment (which may include induction therapy, stem cell transplant, and consolidation) and achieved a good response (VGPR or better) - You are willing to use effective contraception during and for 3 months after the study **You may NOT be eligible if...** - You have not yet received first-line treatment - You have not achieved at least a very good partial response (VGPR) after initial therapy - You are pregnant or planning to become pregnant during the study Talk to your doctor to see if this trial is right for you.